Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other medicines over the next five years.

The Motley Fool • Oct 24, 2026

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Oct 23, 2026

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.

Zacks Investment Research • Oct 23, 2026

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Oct 21, 2026

CRISPR Therapeutics Announces Chief Financial Officer Transition

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.

GlobeNewsWire • Oct 19, 2026

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.

The Motley Fool • Oct 18, 2026

Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.

The Motley Fool • Oct 18, 2026

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.

Zacks Investment Research • Oct 16, 2026

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Oct 12, 2026

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

Substantial revenue from its flagship drug Casgevy should be right around the corner. Investors can expect a pivotal update on CTX310 before the end of the year.

The Motley Fool • Oct 9, 2026